bluuebunny/crossref_metadata_2025_split huggingface dataset:
Renal involvement in patients with non‐Hodgkin's lymphoma: Clinical and pathological features in 23 cases
Authors: Richards M. A. , Mootoosamy I. , Reznek R. H. , Webb J. A. W. , Lister T. A. 
Published: February 2007

AbstractTwenty‐three cases of renal or perirenal involvement by non‐Hodgkin's lymphoma were identified from a restrospective review of computed tomography (CT) scans performed on patients at St Bartholomew's Hospital over an 8‐year period. The histology, clinical features and survival of these patients were examined.Eighteen of the 23 patients had high grade histological subtypes according to the Kiel classification. The majority of cases were identified from scans performed at the time of presentation. In nine cases renal lymphoma was observed in the absence of detectable retroperitoneal lymphadenopathy. Staging was rarely altered by the finding of renal lymphoma as 21 of the 23 patients had involvement of other extranodal sites in addition to the kidney. Survival did not appear to be adversely affected by the presence of renal lymphoma at the time of initial diagnosis. During the same period no cases of renal involvement were identified in patients with Hodgkin's disease, although one patient had perirenal involvement.
Rearrangement of human T cell receptor β and γ chain genes in adult t cell leukemia/lymphoma
Authors: Ohshima K. , Yoshida T. , Kikuchi M. , Masuda Y. , Kimura N. , Satoh H. 
Published: February 2007

AbstractWe studied rearrangement of human T cell receptor genes (TCR) of Cβ, Cγ, Vγ and Jγ in 34 cases of adult T cell leukemia/lymphoma (ATLL), consisting of 29 cases with monoclonally integrated HTLV‐I proviral DNA (ATLL‐W) and five without monoclonal integration (ATLL‐O), in comparison with 12 cases of other peripheral T cell lymphomas (non‐ATLL).All cases of both ATLL and non‐ATLL showed some rearrangement of T cell receptor genes (TCRs) of Cβ. Cγ, Vγ, or Jγ. Rearrangement of TCRβ was found in 28 of 29 cases of ATLL‐W, all cases of ATLL‐O. and eight of 12 cases of non‐ATLL. Rearrangement of TCRγ was observed in 21 of 22 cases of ATLL‐W. and in all cases of ATLL‐O and non‐ATLL. In TCRγ, rearrangement of Cγ was seen in six of 20 cases of ATLL‐W. none of three ATLL‐O cases and three of six cases of non‐ATLL. Vγ rearrangement occurred in 14 of 18 cases of ATLL‐W, one of two cases of ATLL‐O, and three of six cases of non‐ATLL. Rearrangement of Jγ, was found in 16 of 22 cases of ATLL‐W, two of five ATLL‐O cases, and six of seven non‐ATLL cases. Rearrangement was more frequent in ATLL‐W than in ATLL‐O and non‐ATLL. The incidence rate of rearrangement of Vγ families of Vγ1, Vγ2, and Vγ3 was nearly the same in each group, except for deletion of Vγ3, which was often observed in ATLL but was absent in non‐ATLL. These results indicate the usefulness of detection of TCR and HTLV‐I proviral DNA to differentiate ATLL from other T cell malignancies.
Human T‐cell lymphotropic virus type I (HTLV‐I) antibodies in pre‐diagnostic serum of patients with familial adult T‐cell leukemia/lymphoma (ATL)
Authors: Nomura Abraham M. Y. , Yanagihara Eugene T. , Blattner William A. , Ho Gloria Y. F. , Inamasu Melvin S. , Severson Richard K. , Nakamura Jeffrey M. 
Published: February 2007

AbstractIn a study of 7498 American men of Japanese ancestry in Hawaii, 26 incident cases of leukemia or non‐Hodgkin's lymphoma were identified after a follow‐up period of 19 years. Two of the cases, who were brothers, were diagnosed with adult T‐cell leukemia/lymphoma (ATL). Both of these brothers had human T‐cell lymphotropic virus type I (HTLV‐I) antibodies in their stored serum which were obtained 4 and 18 years before diagnosis. None of the 24 patients with other hematologic malignancies or the 26 matched controls were HTLV‐I antibody positive. This finding lends further support for a role of HTLV‐I in the etiology of adult T‐cell leukemia/lymphoma.
Combination of interferon and dexamethasone in refractory multiple myeloma
Authors: San Miguel J. F. , Moro M. , Bladé J. , Guerras L. , Hernandez J. , Jimenez‐Galindo R. , Ortega F. , Gonzalez M. 
Published: February 2007

AbstractThe present pilot study was designed to analyse the efficacy and toxicity of the association of interferon (IFN) and dexamethasone (Dx) in 32 resistant and relapsed myeloma patients. Among the evaluable cases. 15 (68 per cent) responded to treatment (32 per cent achieved an objective response—OR—and 36 per cent a partial response—PR—), the ‘remission’ status lasting for more than one year in six of them. Moreover, four out of the seven OR patients showed a reduction in B.M. plasma cells to < 5 per cent. Five out of 11 patients that were previously refractory to VBAD, that includes high dose dexamethasone (Dx), responded to IFN‐Dx. The protocol was generally well tolerated with only four patients discontinuing therapy due to adverse effects.The present results show that the combination IFN + Dx is a promising therapeutic approach for patients with refractory myeloma.
Expression of differentiation and adhesion molecules in sporadic Burkitt's lymphoma
Authors: Aiello Antonella , Delia Domenico , Fontanella Enrico , Giardini Roberto , Rilke Franco , Porta Giuseppe Della 
Published: February 2007

AbstractThe phenotypic features of 44 cases of sporadic Burkitt's lymphoma (BL) were investigated by monoclonal antibodies (MoAbs). The majority of cases were positive for HLA‐DR (97 per cent), CD19 (100 per cent), CD20 (92 per cent) and CD37 (83 per cent) pan‐B markers, in accordance with the B‐cell derivation of the tumour; the B‐cell restricted markers CD21, CD22 and FMC7 reacted with 28 per cent, 66 per cent and 75 per cent of cases, respectively. Of the mantle zone B‐cell specific MoAbs, CD1c was always negative, whereas CD23 and 2.7 were positive with one and two cases, respectively. CD39 was weakly reactive on two specimens, one of which was CD23+. The germinal centre specific MoAbs CD10 and CD77 (Burkitt's lymphoma antigen) displayed a heterogeneous pattern of reactivity and allowed to identify 4 subgroups: CD10+/CD77+ (44 per cent), CD10+/CD77‐ (15 per cent), CD10‐/CD77+ (36 per cent) and CD10‐/CD77‐ (5 per cent). Of 15 cases tested for the expression of CD11a and CD18 lymphocyte‐function‐associated (LFA‐1) antigens and their ligand ICAM‐1 (CD54), seven were positive and six negative for the three markers, while the other two cases expressed alternatively the two molecules. Analysis of the putative normal BL cell counterpart, identified with the CD77 marker in normal lymphoid tissues, showed that all CD77+ B‐cells were constitutively CD11a+/CD18+, suggesting that BLs are likely to arise from a LFA‐1 positive B‐cell and may down‐regulate these molecules during neoplastic transformation.
PRESENCE OF EPSTEIN‐BARR VIRUS DNA IN NASAL LYMPHOMAS OF B AND ‘T’ CELL TYPE
Authors: Ho F. C. S. , Srivastava G. , Loke S. L. , Fu K. H. , Leung B. P. Y. , Liang R. , Choy D. 
Published: February 2007

AbstractWe studied 12 tumours from 11 Chinese patients with primary nasal lymphoma for presence of Epstein‐Barr Virus (EBV) DNA, using Southern‐blot analysis. These results were correlated with immunophenotype and T‐cell receptor (TcR) or immunoglobulin gene rearrangement patterns. EBV DNA was detected in all nine tumours with a ‘T’ phenotype, in both primary and secondary sites. When the structure of the viral genomic termini was studied using the EcoRI‐Dhet probe, a single clonal episomal band was demonstrated in five tumour samples, with one other case showing a biclonal pattern. However, none of these cases showed clonal rearrangement of TcRβ chain gene, and TcRγ rearrangement was found only in one. The lineage of these phenotypic ‘T’ lymphomas therefore require further studies for confirmation. Two out of three B‐lymphomas were also EBV DNA+; clonal EBV DNA was found in one. Their B‐lineage was confirmed by detection of clonal immunoglobulin gene rearrangements. The association of EBV with an increasing number of lymphomas of different types highlights the need for continued study into its role in oncogenesis.
HYBRID FORM OF HAIRY CELL LEUKEMIA AND CHRONIC LYMPHOCYTIC LEUKEMIA
Authors: Sun Tsieh , Susin Myron , Shevde Nirmala , Teichberg Saul 
Published: February 2007

AbstractWe report a case with mixed features of hairy cell leukemia (HCL) and chronic lymphocytic leukemia (CLL), which may represent a hybrid form of these two entities. Hairy projections were demonstrated on leukemic cells in the peripheral blood. Surface marker studies of blood and spleen specimens by flow cytometry and immunohistochemistry showed immunophenotype characteristic of HCL, namely, monoclonal IgG‐kappa, positive reactions to CD 11c, CD 19, CD 20, CD 22, and HLA‐DR, but negative reactions to CD 3, CD 5, CD 7 and CD 10. The only atypical finding was the absence of CD 25. Immunogenotyping showed rearrangement of heavy‐chain and kappa light chain genes. Leukemic cells were also positive for tartrate‐resistant acid phosphatase (TRAP). A pseudosinus pattern was demonstrated in the spleen. However, the leukemic cells in the spleen showed atypical cytologic features. Clinically, the patient had generalized lymphadenopathy, high leukocyte counts, Coombs' negative hemolysis, hypoimmunoglobulinemia and IgG‐kappa monoclonal gammopathy, features more consistent with CLL than HCL. Although only CD 11c, CD 22, CD 25 and TRAP are characteristic for HLC and CD 5, characteristic for CLL, a panel of eight markers is recommended for the differential diagnosis of HCL, CLL and other low‐grade B‐cell neoplasms, which may share some common features, making a clear‐cut diagnosis difficult.
Non‐Hodgkin's lymphomas involving the female genital tract
Authors: Liang Raymond , Chiu Edmond , Loke S. L. 
Published: February 2007

AbstractThirteen female patients with lymphomas involving the genital tract were studied. Their median age was 50 years. There were three cases of stage I disease, one stage II and nine stage IV. The gastrointestinal tract was commonly involved in patients with disease in the ovary. The histology was mostly intermediate or high grade according to the Working Formulation. Immunophenotyping was performed in six patients and they were all B‐cell tumours. There appeared to have a strong association between gastrointestinal involvement and ovarian disease. All patients received combination chemotherapy with or without additional radiotherapy and the survival of patients with stage I and II disease appeared to be superior to those with stage IV disease. However, the difference observed did not reach statistical significance because of small patient number. It remains uncertain whether lymphomas of the female genital tract by itself carries a poorer prognosis than the nodal lymphomas of comparable stage and histology.
Failure of mithramycin to control the myeloid blast phase of chronic granulocytic leukemia: A report on nine patients and review of the literature
Authors: Johnson P. R. E. , Yin J. A. Liu , Narayanan M. N. , Geary C. G. , Love E. M. , Cinkotai K. I. 
Published: February 2007

AbstractAfter reports of the successful use of mithramycin and hydroxyurea in the myeloid blast phase of chronic granulocytic leukemia, we treated nine patients according to the protocol devised by Koller and Miller (1986). There were no complete responses, but one patient had a partial response with a transient return to the chronic phase. Of the remaining eight patients, two experienced lessening of bone pains, and one a reduction in spleen size, but without hematological improvement. The regimen was associated with significant toxicity, and no overall survival advantage. We present a review of published data regarding the use of mithramycin in chronic granulocytic leukemia which supports the results in our series. The combination of mithramycin and hydroxyurea is largely ineffective in the blast phase of chronic granulocytic leukemia, but may be of value in the accelerated phase.
Prognostic value of serum beta 2 microglobulin in primary gastric lymphoma
Authors: Avilés Agustin , Díaz‐Maqueo José C. , Rodriguez Leticia , García Edna L. , Guzmán Renaldo , Talavera Alejandra 
Published: February 2007

AbstractSixty‐eight previously untreated patients with primary gastric non‐Hodgkin's lymphoma (NHL) available for analysis, were entered in a study in which the prognostic significance of serum beta 2 microglobulin levels were evaluated.The serum beta 2 microglobulin was the most significant prognostic factor. Patients with high levels (> 3.5 μg/mL) had a relapse‐free survival (RFS) of 36 months, while the median RFS has not been reached in patients with normal levels (p<0.001). The 5‐year survival was 80 per cent for patients with normal levels, statistically significant when compared to patients with high levels: 38 per cent (p> 0.001).Serum beta 2 microglobulin should be included in the initial staging of patients with primary extranodal NHL and patients with high levels should be treated more aggressively.
Severe legionella pneumophila infection in a patient with hairy cell leukemia in partial remission after a interferon treatment
Authors: Radaelli Franca , Langer Martin , Chiorboli Ornella , Proietti Daniela , Baldini Luca 
Published: February 2007

AbstractLegionella pneumonia is an increasingly frequently reported complication in immunocompromised patients, particularly patients with hairy cell leukemia (HCL) in active phase. The most important predisposing factor seems to be the quantitative and qualitative defect of the monocytic‐macrophagic system characteristic of HCL. We report a case of severe Legionella pneumophila infection with multisystem involvement in a patient with HCL in stable partial remission obtained after therapy with interferon. In our patient recovery of a normal monocyte count did not protect against a legionella infection, indicating that this pathogen should always be sought in HCL patients even those in clinical and hematologic remission. Early diagnosis and appropriate treatment may reduce the mortality of this serious complication.
Radiotherapy as salvage treatment in patients with hodgkin's disease or non‐hodgkin's lymphoma relapsing after initial chemotherapy
Authors: Kirkove Carine , Timothy Adrian R. 
Published: February 2007

AbstractThe prognosis of relapsing Hodgkin's disease (HD) and high grade aggressive non‐Hodgkin's lymphoma (NHL) is generally poor since many of these patients fail to respond to second line chemotherapy. Radiation therapy has been reported as an effective but seldom used, alternative treatment. We have observed very encouraging results with salvage radiotherapy in a highly selected group of eight lymphoma patients (six with HD and two with high grade NHL), suffering mainly from nodal relapse. The literature on the use of radiation therapy after chemotherapy failures in HD and NHL is reviewed.
Sequential versus alternating chemotherapy for high grade non‐hodgkin's lymphomas: A randomized multicentre trial
Authors: Köppler H. , Pflüger K. H. , Eschenbach I. , Pfab R. , Birkmann J. , Zeller W. , Steinhauer E. U. , Gropp C. , Oehl S. , Lötzke E. , Kuhn H. , Drings P. , Gossmann H. H. , Lennert K. , Stein H. , Havemann K. 
Published: February 2007

AbstractIn a multicentre phase III trial 146 previously untreated patients with high grade non‐Hodgkin's lymphomas stage II–IV were randomized to receive either four cycles of CHOEP (cyclophosphamide 750 mg/m2 iv d 1, doxorubicin 50 mg/m2 iv d 1, vincristine 2 mg iv d 1, etoposide 100 mg/m2 iv d 3–5, prednisolone 100 mg po d 1–5) (treatment arm A), or four cycles of chemotherapy with hCHOP (cyclophosphamide 1200 mg/m2 iv d 1, doxorubicin 40 mg/m2 iv d 1 + 2, vincristine 2 mg iv d 1, prednisolone 100 mg po d 1–5) alternating with IVEP (ifosfamide 1500 mg/m2 iv d 1–5, vindesine 3 mg/m2 iv d 1, etoposide 120 mg/m2 iv d 3–5, prednisolone 100 mg po d 1–5) (treatment arm B). After four cycles of chemotherapy an involved field irradiation with a total dose of 35 Gy was given to all patients in complete or partial remission without persisting extranodal disease. A complete response (CR) was seen in 124/146 patients (86 per cent) with 87 per cent CR in arm A versus 83 per cent CR in arm B. During a median follow‐up of 17 months (range 2–40) 30 patients relapsed (16 patients arm A, 14 patients arm B). The overall survival at 40 months is projected to be 71 per cent versus 70 per cent for arm A and B, respectively. Disease‐free survival is projected to be 68 per cent in arm A and 59 per cent in arm B at 40 months. So far, the differences in CR, survival and disease‐free survival are not statistically significant. Toxicity of all regimens was acceptable, however, with a significant morbidity and one treatment‐related death in patients > 70 years after hCHOP. Main side effects were mild nausea/vomiting, leukopenia and fever/infection associated with leukopenia.In conclusion both treatment modalities produced high complete remission rates. A longer follow‐up will be needed to exclude differences in over‐all and disease‐free survival.
Treatment of terminal‐phase chronic myelogenous leukemia with intermediate‐dose cytarabine and hydroxyurea
Authors: Lazzarino M. , Morra E. , Brusamolino E. , Alessandrino E. P. , Orlandi E. , Pagnucco G. , Castagnola C. , Bernasconi P. , Merante S. , Bonfichi M. , Castelli G. , Canevari A. , Bernasconi C. 
Published: February 2007

AbstractWe used intermediate doses of Ara‐C (IDAra‐C) in the treatment of 15 patients with chronic myelogenous leukemia (CML) in blast crisis and, combined with hydroxyurea, in 20 CML patients in accelerated phase. Patients with blastic CML received intensive 5‐day courses of IDAra‐C 600 mg/m2 every 12 h as a 2‐h infusion. Of 15 patients, three achieved complete response (CR) and three partial response (PR), for an overall response rate of 40 per cent. All patients developed severe leukopenia and thrombocytopenia, and two died in hypoplasia. Except nausea and vomiting requiring medication, other nonhematologic toxicities were uncommon. Median response duration was 4 months (range 1 to 7 months). Survival was 5 months for responders and 1·5 months for nonresponders. Patients with CML in accelerated phase were treated with two‐day courses of IDAra‐C 600 mg/m2 every 12 h by 2‐h infusion, every two‐three weeks. Daily hydroxyurea 1–1·5 g/day was administered between courses. Of 20 patients, 15 (75 per cent) achieved a good PR with rapid improvement of the symptoms of disease acceleration. The median duration of response was 11 months (range 3 to 38 months); duration was over 24 months in five patients. The median survival from the start of IDAra‐C was 13 months for responders and 3·5 months for nonresponders. We conclude that IDAra‐C is an effective approach for CML in terminal phase. Its use in 5‐day induction courses for blast crisis CML has a response rate comparable to that achieved with high‐dose Ara‐C. In patients in accelerated phase, the combination of short courses of IDAra‐C with hydroxyurea is a well‐tolerated treatment able to improve substantially the clinical and hematologic symptoms of disease progression.
A pilot study of epirubicin and chlorambucil in the treatment of chronic lymphocytic leukemia (CLL)
Authors: Smith G. M. , Child J. A. , Milligan D. W. , McEvoy M. A. , Murray J. A. 
Published: February 2007

AbstractIn a pilot study of the combination of epirubicin and chlorambucil in the treatment of chronic lymphocytic leukemia (CLL), 10 patients with advanced or progressive disease were treated in four centres. Up to a total of 15 course in individual patients were given. Toxicity was relatively mild with nausea due to epirubicin being the most commonly reported side‐effect. One patient developed a probable septicemia during a period of neutropenia. In another patient who died from probable Pneumocystis carinii pneumonia (PCP) after only one course of therapy, death could not be regarded as necessarily treatment‐related. In seven previously untreated patients, one complete response and four partial remissions were seen. All three previously treated patients showed partial remissions
Quantitative study of KI‐67 antibody staining in 46 T‐cell malignant lymphomas using image analysis
Authors: Caulet S. , Brousset P. , Schoevaert D. , Chttal S. M. , Delsol G. , Audouin J. , Diebold J. 
Published: February 2007

AbstractImage analysis with a SAMBA 2005 (ALCATEL‐TITN, Co) was used to quantify the Ki‐67 stained area percentage in 46 T‐cell malignant lymphomas (T‐ML), classified according to the updated Kiel classification. This parameter demonstrated correlation with the number of Ki‐67‐positive cellular profiles (r = 0.88, P < 0.001) and was more reproducible than cell counting.A significant difference was found between low and high grade T‐ML (mean values ± SEM respectively of 10.20 ± 1.82 per cent and 25.63 ± 3.15 per cent). The most interesting findings were that: (1) AILD‐type T‐ML showed an intermediate proliferation rate (15.55 ± 2.72 per cent) between pleomorphic T‐ML with medium and with large cells (respectively 12.53 ± 3.64 per cent and 22.43 ± 3.46 per cent), both of which belong to the high grade malignancy group. This finding is in accordance with the poor prognosis of this subtype despite its classification in the low grade malignancy group. (2) Subclassification of the pleomorphic MLs according to the predominance of small, medium or large cells, demonstrated significant differences between these three subtypes. However, the great overlap of values between pleomorphic T‐ML with medium and with large cells, seems to indicate that the Subclassification of these two subtypes is less valid. (3) A wide range of values with overlap was observed in AILD‐type ML, in pleomorphic with medium or large cells and in lymphoblastic T‐ML: for these T‐ML with variable survival courses, the Ki‐67 area percentage, one parameter of proliferative activity, appears worth studying as a prognostic factor.
Recombinant human granulocyte macrophage colony stimulating factor following alternating non cross resistant chemotherapy in hodgkin's disease
Authors: Oza A. M. , Leahy M. , Dorey E. , Davis C. L. , Amess J. , Horton M. , Rohatiner A. Z. S. , Wrigley P. F. M. , Lister T. A. 
Published: February 2007

AbstractFourteen patients with Hodgkin's disease (two previously untreated, 12 following relapse or with refractory disease) were treated with a combination chemotherapy regimen comprising chlorambucil, vinblastine, procarbazine, prednisolone, etoposide, vincristine and adriamycin administered on days 1–8. Recombinant human granulocyte‐macrophage colony stimulating factor (rhGM‐CSF) (mammalian glycosylated, Sandoz Schering‐Plough) was administered after alternate cycles of chemotherapy from day 10 for 7 days by continuous intravenous (i.v.) infusion in 12 patients in a dose finding study (dose: 2 μg/kg/day in four patients. 4 μg/kg/day in four patients and 8 μg/kg/day in four patients) and by daily subcutaneous (s/c) injections in two patients (8 μg/kg/day). There was a rapid peripheral leucocytosis following the rhGM‐CSF, reaching a peak at 1–2 days in 12/14 patients. The initial leucocytosis was composed of neutrophils followed by a rise in immature myeloid cells. There was no difference observed in the duration or depth of the nadir following chemotherapy or in the rate of recovery of peripheral white cell counts between cycles with and without rhGM‐CSF in patients treated with 2 and 4 μg/kg/day. At the dose of 8 μg/kg/day, 3/6 patients had a shorter nadir duration in the cycle with rhGM‐CSF, compared with cycle without rhGM‐CSF. There was no difference in frequency of infection in cycles with and without rhGM‐CSF. Following chemotherapy, six patients achieved clinical remission, six partial remission and two had progressive disease.